Navigation Links
Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for MDV3100
Date:10/26/2009

SAN FRANCISCO, Oct. 26 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will hold a teleconference at 8:30 a.m. Eastern Time tomorrow, Tuesday, October 27, to discuss partnering plans for MDV3100, Medivation's investigational drug which is currently in Phase 3 testing for the treatment of prostate cancer.

Teleconference/Webcast Details

To participate in the live call on Tuesday, October 27, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), please dial 888-280-4443 for domestic callers and 1-719-457-2638 for international callers. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases. With Pfizer, Medivation is conducting a broad dimebon clinical development program that includes several Phase 3 trials assessing the efficacy and safety of dimebon taken alone or in combination with other Alzheimer's medications in patients with mild, moderate and severe Alzheimer's disease. The companies are also conducting a Phase 3 trial of dimebon in Huntington disease. A Phase 3 clinical trial of MDV3100 in patients with castration-resistant prostate cancer is under way. For more information, please visit us at http://www.medivation.com.

SOURCE Medivation


'/>"/>
SOURCE Medivation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Medivation Announces Participation in Upcoming Conferences
2. Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 CONNECTION Trial of Dimebon in Patients With Alzheimers Disease
3. Medivation Announces Pricing of Public Offering
4. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
5. Medivation Announces Upcoming Scientific Presentations at Medical Conferences
6. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
7. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
8. Medivation Presents New Data on Dimebons Novel Mechanism of Action
9. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
10. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
11. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 “We are honored to ... said Ven Thangaraj, CEO of Radiant Sage. “We are ... taking the imaging corelab market to a different level. ... research organizations to efficiently and effectively manage the massive ... to be analyzed and read by trained physicians. Being ...
(Date:8/27/2014)... 2014 Research and Markets has ... Pulp & Paper Industry Report 2014" report to ... Pulp & Paper Industry Report 2014 is a professional ... global enzyme for pulp & paper industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:8/27/2014)... 2014 Riviera Beach, Florida based ... creation of the Sancilio Scientific Advisory Board (SSAB). ... philosophy of looking to nature for pharmaceutical advancements, ... are based on sound scientific data, analyses, expertise ... provides a vehicle for SCI to receive peer ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Remcom announces ... with new features for the biomedical industry. ... enhanced Biological Thermal Sensor, exclusive to the Bio-Pro version ... version of XFdtd, developed to calculate the biological effects ... has been added to all versions to expand engineers’ ...
Breaking Biology Technology:Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2Global Enzyme for Pulp & Paper Industry Report 2014 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 3
... Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biopharmaceutical ... therapeutics for,the treatment of solid and hematologic cancers, today ... upcoming conferences:, Rodman & Renshaw 10th Annual Healthcare ... Wednesday, November 12, 2008, 2:00 p.m. EST, ...
... MINNEAPOLIS, Nov. 3 ATS Medical, Inc.,(Nasdaq: ... state-of-the-art cardiac,surgery products and services, today announced ... development of the ATS Forcefield(TM),technology. The animal ... regarding the inhibition of platelet adhesion on ...
... Journal published,an article on October 29th describing the ... and featuring quotes from,President and founder Dr. Timothy ... Transfusions: New Efforts to Recycle Blood and Treat ... part of the "The Informed Patient",series written by ...
Cached Biology Technology:Sunesis to Present at Upcoming Conferences 2ATS Forcefield Anti-platelet Technology Continues to Demonstrate Positive Results 2ATS Forcefield Anti-platelet Technology Continues to Demonstrate Positive Results 3Wall Street Journal Highlights Blood Management, Strategic Healthcare Group LLC, and Dr. Timothy Hannon 2
(Date:8/28/2014)... most important crop-producing countries will be fully saturated with ... trends continue, according to a new study led by ... types can already be found in around half the ... advances at its current rate, scientists fear that a ... by pests within the next 30 years. , Crop ...
(Date:8/27/2014)... MADISON, Wis. The mechanical force that a single fungal ... seem vanishingly small, but it plays a heavy role in ... biology. In fact, it may not be too much of ... onto land without the ability to respond to the touch ... Jean-Michel An, a professor of agronomy at the University of ...
(Date:8/27/2014)... -- WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced that it ... units of common stock and warrants at a price ... million, prior to deducting underwriting discounts and commissions and ... warrants are immediately separable and will be issued separately.  ... consists of 2,000 shares of common stock and 2,000 ...
Breaking Biology News(10 mins):New study charts the global invasion of crop pests 2A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3
... major component in the spice turmeric, when combined with ... and neck cancer cell growth, researchers with UCLA,s Jonsson ... widely used in South Asian and Middle Eastern cooking, ... attributed to its anti-inflammatory effects. Previous studies have shown ...
... and tissues in our bodies grow, develop and interact ... microbial pathogens that invade our bodies and cause infectious ... the methods of culturing and studying human cells have ... impermeable surfaces. While such 2-D culturing and modeling efforts ...
... of Leeds plant scientists has uncovered a snapshot of evolution ... million years ago led flowers to make male and female ... week in the Proceedings of the National Academy of ... a perfect example of how diversity stems from such genetic ...
Cached Biology News:Major component in turmeric enhance effect of chemotherapy drug in head and neck cancer 2Major component in turmeric enhance effect of chemotherapy drug in head and neck cancer 3The world is not flat: Exploring cells and tissues in three dimensions 2The world is not flat: Exploring cells and tissues in three dimensions 3The world is not flat: Exploring cells and tissues in three dimensions 4100-million-year-old mistake provides snapshot of evolution 2
... Spring offers a large collection of ... fetal tissuea, cell lines, and mouse ... in pHD9 vector. The size of ... be from 200bp to 1000bp by ...
... The IDS Corticosterone kit is a competitive ... corticosterone in mouse or rat serum or ... sole, corticosteroid in rats and mice, and ... birds and reptiles. Most mammals produce both ...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Rabbit polyclonal to Nck alpha ( Abpromise for all tested applications). entrezGeneID: 4690 SwissProtID: P16333...
Biology Products: